![]() We caution investors that amounts presented in accordance with our definitions of any of the Non-GAAP Measures may not be comparable to similar measures disclosed by other issuers, because some issuers calculate certain of the Non-GAAP Measures differently or not at all, limiting their usefulness as direct comparative measures. ![]() ĮBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio, Medical Margin and Cost of Care Delivery Margin are non-GAAP financial measures (collectively, the "Non-GAAP Measures") and have certain limitations, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under GAAP. Securities and Exchange Commission (the "SEC") and will be available in the Investor Relations section of Babylon’s website at. The Company is not providing updated guidance at this time.īabylon’s Quarterly Report on Form 10-Q for the first quarter of 2023 is being filed today with the U.S. In light of the Company’s announcement today concerning an interim financing and proposed take private transaction to be led by AlbaCore Capital LLP and affiliates, the Company has withdrawn its full-year 2023 revenue and Adjusted EBITDA guidance, and its mid-2024 target for Adjusted EBITDA profitability, issued on March 9, 2023. Private business grew 83% YoY, with over 186K appointments delivered in Q1 2023įinancial Guidance, Balance Sheet Cash and Other Important Information Improved VBC Revenue mix, exiting two Medicaid contracts and going live on Januwith our digital-first Commercial Exchange product, Ambetter, resulting in nearly 60% of our VBC revenue coming from non-Medicaid membersĬontinued disciplined execution of previously announced cost reduction initiatives, including completion of the sale of a non-core businessĪmbetter digital-first service for Commercial members exceeded projections with 38% membership growth YTD, members are 12+ times faster to register and have demonstrated 8x engagement rates, higher than any of our other cohortsĪppointments in our U.K. Net income in Q1 2022 included a $78.8 million gain primarily relating to the Company going public.Īdjusted EBITDA totaled $(45.8) million, a (14.7)% Adjusted EBITDA Margin, compared to $(82.6) million Adjusted EBITDA, or (31.0)% Adjusted EBITDA Margin, in Q1 2022. Net loss totaled $63.2 million, a (20.3)% Net loss margin compared to Net loss of $29.1 million, a (10.9)% Net loss margin in Q1 2022. ![]() This was primarily due to the growth in VBC revenue, which increased by 17% year-over-year to $287.5 million in Q1 2023. Total revenue was $311.1 million compared to $266.4 million, a 1.2x year-over-year increase of $44.7 million. AUSTIN, Texas & LONDON, May 10, 2023-( BUSINESS WIRE)- Babylon Holdings Limited (NYSE: BBLN) ("Babylon" or the "Company") today announced its financial and operating results for the first quarter ended March 31, 2023.Ĭomparison of the following financial results for the three months ended March 31, 2023, to the three months ended March 31, 2022:
0 Comments
Leave a Reply. |